Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

Table 2

Differences of pretreatment serum levels of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma treatment responders and nonresponders.

	Treatment responders (median)	Treatment nonresponders (median)	𝑃-value
HGF diagnosis	2139,0	1627,0	0,114
HGF relapse	1365,0	1549,0	0,958
SYN diagnosis	151,0	46,2	0,041
SYN relapse	46,9	78,6	0,589
OPN diagnosis	131,5	110,8	0,448
OPN relapse	60,3	76,4	0,133

HGF: hepatocyte growth factor (pg/mL), SYN: syndecan-1 (ng/mL), OPN: osteopontin (ng/mL). Treatment responders: patients achieving ≥ partial remission after treatment; nonresponders: patients who did not reach partial remission and/or were progressing after treatment.
Statistical estimation was done using Mann-Whitney test at 𝑃<0,05. Only the pretreatment serum levels of soluble syndecan-1 showed borderline significant differences in comparison of treatment responders and nonresponders.